Congo Ebola Response Faces Funding, Security and Vaccine Challenges
The Democratic Republic of Congo is confronting its largest recorded Ebola outbreak as emergency funding nears exhaustion and front-line teams face violence, misinformation and severe logistical constraints.
More than 2,500 people have died, while approximately 4,400 cases have been officially identified. Officials believe the actual total is higher. The outbreak, caused by the Bundibugyo Ebola strain, is expanding across an area larger than France, according to senior United Nations coordinator Julien Harneis.
He said the response is not keeping pace and warned that available emergency funds could run out within weeks. Health personnel are also being directly affected. About 160 health-care workers have contracted Ebola, and 43 have died. Responders have reported more than 260 attacks in six months, including assaults on facilities and ambulances; eight health workers were killed. Aid officials link some hostility to fear, conspiracy theories and restrictions on traditional burials.
Vaccination efforts are proceeding despite uncertainty. Congo has requested doses from the global vaccine stockpile, and 70,000 doses of Ervebo have been allocated. Ervebo is approved against the Zaire Ebola strain, not Bundibugyo. Of the allocated supply, 20,000 doses will be used in a late-stage trial to determine whether it offers protection against the current strain. The World Health Organization says human protection remains unknown and that clinical evidence is needed.
The response is further complicated by three decades of conflict, reduced humanitarian capacity and disrupted banking services. The suspension of commercial flights has limited cash deliveries to banks, creating difficulties in paying tens of thousands of outbreak workers.
Officials say containment may take at least six months. They also warn that Congo’s central location raises concerns about transmission beyond its borders. The immediate priorities are securing funds, protecting responders, maintaining public trust, expanding surveillance and establishing whether available vaccines can help slow the expanding outbreak.